Physicians' Academy for Cardiovascular Education

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK

Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden

SGLT2 inhibitor treatment may now be considered in broader T2DM population

3' education - Nov. 11, 2018 - Steve Wiviott, MD - Boston, MA, VS.

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands

In a primary prevention setting of diabetes patients, aspirin did not give overall benefit

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Weight loss agent showed CV safety in high-risk patients with overweight or obesity

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No CV benefit with omega-3 fatty acid supplements

3' education - Aug. 26, 2018

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

SGLT2 inhibitor treatment is beneficial in T2DM patients with a broad range of ejection fractions

News - Mar. 19, 2019

ACC 2019 An analysis of DECLARE-TIMI 58 showed that dapagliflozin was associated with reduced hospitalization for HF and CV death across a range of EF. Benefit seems largest in HFrEF.

New ACC/AHA primary prevention guideline takes a patient-centered approach

News - Mar. 17, 2019

ACC 2019 The new guideline promotes a healthy lifestyle throughout life, and encourages physicians to assess social determinants of health to optimally implement the recommendations.

Host genetics influences gut microbiome composition, which affects glucose metabolism

Literature - Mar. 6, 2019 - Sanna S et al., - Nature Genetics 2019

A mendelian randomization approach to identify gut bacteria with a causal effect on metabolic traits, revealed causal links between gut-produced short-chain fatty acids and the insulin response and risk of T2DM.

Sex differences in trends, treatment and control of CV risk factors in the US from 2001-2016

Literature - Mar. 5, 2019 - Peters SA, et al. - Circulation 2019

A study with representative US citizens showed similar trends for most CV risk factors between men and women from 2001 to 2016, with the exception of BMI and total cholesterol, and sex differences for control of hypertension, diabetes and dyslipidemia.

DAPT with P2Y12-inhibitor lowers CV events in T2DM patients with established CAD

News - Feb. 25, 2019

The Phase III THEMIS trial demonstrated that ticagrelor, taken in conjunction with aspirin, reduced MACE vs aspirin alone, in patients with CAD and T2DM without prior MI or stroke.

Increasing prevalence rates of modifiable risk factors in relatively young patients hospitalized for AMI

Literature - Feb. 19, 2019 - Yandrapalli S et al. - JACC 2019
In a retrospective cohort study, major modifiable atherosclerotic risk factors were highly prevalent among adults aged 18-44 years hospitalized for a first AMI. Except for dyslipidemia, prevalence rates of risk factors progressively increased over time.

In a retrospective cohort study, major modifiable atherosclerotic risk factors were highly prevalent among adults aged 18-44 years hospitalized for a first AMI. Except for dyslipidemia, prevalence rates of risk factors progressively increased over time.

Large meta-analysis confirms efficacy of statins in primary CVD prevention, but individual benefit-harm profiles vary

Literature - Feb. 18, 2019 - Yebyo HG et al. - Am Heart J 2019

This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.

DPP-4 inhibitor meets primary endpoint in CV outcome trial

News - Feb. 14, 2019

The long-term CAROLINA trial met its primary endpoint, defined as non-inferiority of linagliptin vs. glimepiride in time to first occurrence of 3P-MACE in adults with T2DM .

Treatment with GLP-1RA results in reduction of MACE in type 2 diabetes patients with established CVD

Literature - Feb. 12, 2019 - Hernandez AF et al. - The Lancet 2018

Albiglutide was superior to placebo with respect to MACE in T2DM patients in the Harmony Outcomes trial without differences in serious adverse events.

Two choices of drugs that reduce CV risk in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD
Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom
Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.

Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK
Prof. Neil Poulter discusses lessons that can be drawn from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.

Prof. Neil Poulter discusses lessons that can be drawn from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.